Abliva — Capital/Financing Update 2021

Apr 30, 2021

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION, WHERE SUCH ACTIONS ARE SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER REGARDING ANY SECURITIES IN ABLIVA.

Abliva publishes prospectus and new information contained in the prospectus

Abliva AB (Nasdaq Stockholm: ABLI) ("Abliva" or "the Company"), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the prospectus that Abliva has prepared regarding admission to trading of 74,065,306 shares on Nasdaq Stockholm as a result of the directed issue of shares resolved by the Board of Directors on 30 March 2021 with subsequent approval by the General Meeting on 29 April 2021 (the "Directed Issue") has today been approved and registered by the Swedish Financial Supervisory Authority ("SFSA"). Due to regulatory requirements, the prospectus presents new information that has not previously been published, including information on the Company's capital structure (presented as of February 28, 2021) and a detailed presentation of the use of the proceeds from the directed issues resolved by the Board of Directors on 30 March 2021.

Prospectus

The prospectus prepared regarding admission to trading of 74,065,306 shares on Nasdaq Stockholm as a result of the Directed Issue has today, on 30 April 2021, been approved and registered by the SFSA. The prospectus can be obtained from Abliva and Erik Penser Bank and is available on Abliva's website (www.abliva.com) and on Erik Penser Bank's website (www. penser.se). The prospectus will also be available on SFSA's website (www.fi.se).

Information regarding the use of the issue proceeds

The proceeds of 80 MSEK from both of the directed issues resolved by the Board of Directors on 30 March 2021 are planned to be used in accordance with the priority order specified below:

• costs related to Phase 1 regarding KL1333, 20 percent,
• costs related to preparations for Phase 2/3 KL1333, 60 percent,
• costs related to the development of NV354, 10 percent, and
• general business purposes, 10 percent

New financial information contained in the Prospectus

Stated in the Prospectus is Abliva's capital structure, net debt and assets as of 28 February 2021. This is due to regulatory rules which require that financial information regarding the capital structure must not be older than 90 days when the Prospectus is published. This information has not previously been published and the tables below provide this information. Note that only interest-bearing liabilities are reported in the tables. The information has not been reviewed by the Company's auditor.

Press Release

Abliva AB (publ), 556595-6538 30 April 2021 09:50:00 CEST - Lund, Sweden

Equity and liabilities as of 28 February 2021

kSEK	2021- 02-28	Adjustments³	Adjustments for the directed issues
Current interest-bearing liabilities
With guarantee	-	-	-
With collateral¹	211	-	211
Unsecured credit	-	-	-
Total current interest-bearing liabilities	211	-	211
Long term interest-bearing liabilities
With guarantee	-	-	-
With collateral¹	90	-	90
Unsecured credit	-	-	-
Total long-term interest-bearing liabilities	90	-	90
Equity²
Share capital	14,817	5,333	20,150
Other capital contribution	660,025	74,667	734,692
Reserves	616	-	616
Retained earnings including profit for the year	-535,096	-	-535,096
Total equity	140,362	80,000	220,362
Total equity and interest-bearing liabilities	140,663	80,000	220,663

Abliva AB (publ) - the mitochondrial medicine company. The company is listed on Nasdaq Stockholm, Small Cap, under the ticker symbol ABLI. ¹ Refers to leasing liability right of use.

Abliva AB (publ), 556595-6538 30 April 2021 09:50:00 CEST - Lund, Sweden

¹ Refers to leasing liability right of use.

² As of 31 December 2020.

³ Adjustments due to the directed issues the directed issues resolved by the Board of Directors on 30 March 2021.

Net debt as of 28 February 2021

kSEK	2021- 02-28	Adjustments²	Adjustments for the directed issues
A. Cash and cash equivalents	-	-	-
B. Other cash and liquid assets¹	52,954	80,000	132,954
C. Easily realisable securities	-	-	-
D. Total liquidity (A+B+C)	52,954	80,000	132,954
E. Current receivables	-	-	-
F. Current liabilities to credit institutions	-	-	-
G. Current portion of long-term liabilities	211	-	211
H. Other current interest-bearing liabilities	-	-	-
I. Total current interest-bearing liabilities (F+G+H)	211	-	211
J. Net current interest-bearing liabilities (I-E-D)²	-52,743	-80,000	-132,743
K. Long-term liabilities to credit institutions	-	-	-
L. Issued bonds	-	-	-

Press Release

Abliva AB (publ), 556595-6538 30 April 2021 09:50:00 CEST - Lund, Sweden

M. Other long-term interest-bearing liabilities	90	-	90
N. Total long-term interest-bearing liabilities (K+L+M)	90	-	90
O. Net debt (J+N)	-52,653	-80,000	-132,653

¹ Consists of available liquid assets on a bank account.

² Adjustments due to the Directed Issue

Advisors

Erik Penser Bank AB is financial advisor and Cirio Advokatbyrå AB is legal advisor to Abliva in connection with the Directed Issue.

For more information, please contact:

Catharina Johansson, Deputy CEO, CFO & VP Investor Relations +46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)

Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) info@abliva.com, www.abliva.com

Subscribe to our news: https://abliva.com/posts/news-subscription/ Follow us on LinkedIn:https://www.linkedin.com/company/abliva Subscribe to our YouTube channel: https://www.youtube.com/channel /UChqP7Ky5caXtp72CELhD6Mg

Abliva – Delivering mitochondrial health

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company is focused on two projects. KL1333, a powerful NAD⁺ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, is in preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Press Release

Abliva AB (publ), 556595-6538 30 April 2021 09:50:00 CEST - Lund, Sweden

Important information

Release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions according to law and persons in those jurisdictions, in which this press release has been announced or distributed, should inform themselves of and follow such legal restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Abliva in any jurisdiction.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. The information in this press release may not be announced, published or distributed to Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland, the United States or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.

This press release is not a prospectus. Abliva has not authorized any offer to the public of shares or rights in any member state of the EEA and no prospectus has been prepared or will be prepared in connection with the Directed issue.

Attachments

Abliva publishes prospectus and new information contained in the prospectus